amlodipine has been researched along with Renal Artery Stenosis in 8 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Renal artery stenosis is among the most common curable causes of hypertension." | 2.70 | Resistance to antihypertensive medication as predictor of renal artery stenosis: comparison of two drug regimens. ( Deinum, J; Derkx, FH; Krijnen, P; Postma, CT; Schalekamp, MA; van Jaarsveld, BC; Woittiez, AJ, 2001) |
| "Aggressive treatment of hypertension resulted in complete resolution of the clinical and radiologic features of the syndrome." | 1.43 | Does this patient have hypertensive encephalopathy? ( Argyropoulou, MI; Christopoulou, F; Elisaf, M; Kosta, P; Rizos, EC, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jafari, R | 1 |
| Rostami, Z | 1 |
| Nikpoor, M | 1 |
| Javanbakht, M | 1 |
| Ghahroudi, MS | 1 |
| Hosseini, MS | 1 |
| Einollahi, B | 1 |
| Pathak, AS | 1 |
| Rojas, M | 1 |
| Stouffer, GA | 1 |
| Cooper, CJ | 1 |
| Murphy, TP | 1 |
| Cutlip, DE | 1 |
| Jamerson, K | 1 |
| Henrich, W | 1 |
| Reid, DM | 1 |
| Cohen, DJ | 1 |
| Matsumoto, AH | 1 |
| Steffes, M | 1 |
| Jaff, MR | 1 |
| Prince, MR | 1 |
| Lewis, EF | 1 |
| Tuttle, KR | 1 |
| Shapiro, JI | 1 |
| Rundback, JH | 1 |
| Massaro, JM | 1 |
| D'Agostino, RB | 1 |
| Dworkin, LD | 1 |
| Christopoulou, F | 1 |
| Rizos, EC | 1 |
| Kosta, P | 1 |
| Argyropoulou, MI | 1 |
| Elisaf, M | 1 |
| Campbell, P | 1 |
| Singh, KP | 1 |
| Schuchard, G | 1 |
| Jain, K | 1 |
| White, WB | 1 |
| van Jaarsveld, BC | 2 |
| Derkx, FH | 2 |
| Krijnen, P | 3 |
| Pieterman, H | 1 |
| Man in't Veld, AJ | 1 |
| Woittiez, AJ | 2 |
| Dees, A | 2 |
| Postma, CT | 2 |
| Schalekamp, MA | 2 |
| van Jaarsveld, B | 1 |
| Bartelink, A | 1 |
| Derkx, F | 1 |
| Man in't Veld, A | 1 |
| Schalekamp, M | 1 |
| Deinum, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)[NCT00081731] | Phase 3 | 947 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 77 |
| Stenting | 68 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 20 |
| Stenting | 20 |
Only the first event per participant is included in the composite (NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 169 |
| Stenting | 161 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 26 |
| Stenting | 27 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 27 |
| Stenting | 30 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 3 |
| Stenting | 4 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 16 |
| Stenting | 12 |
4 trials available for amlodipine and Renal Artery Stenosis
| Article | Year |
|---|---|
Stenting and medical therapy for atherosclerotic renal-artery stenosis.
Topics: Aged; Amlodipine; Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic A | 2014 |
'Hypertension resistant to two-drug treatment' is a useful criterion to select patients for angiography: the 'Dutch Renal Artery Stenosis Intervention Cooperative' (DRASTIC) study.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiography; Antihypertensive Agents; Atenolol; Drug Resistance | 1996 |
The Dutch Renal Artery Stenosis Intervention Cooperative (DRASTIC) Study: rationale, design and inclusion data.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiography; Angioplasty, Balloon; Angiotensin-Converting Enzym | 1998 |
Resistance to antihypertensive medication as predictor of renal artery stenosis: comparison of two drug regimens.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cohort Studi | 2001 |
4 other studies available for amlodipine and Renal Artery Stenosis
| Article | Year |
|---|---|
Detection of significant left renal artery stenosis caused by fibromuscular dysplasia with selective angiography.
Topics: Amlodipine; Angioplasty, Balloon; Antihypertensive Agents; Computed Tomography Angiography; Drug Com | 2020 |
Expression of Cyr61 in ApoE
Topics: Amides; Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Apolipoproteins E; Blood Press | 2021 |
Does this patient have hypertensive encephalopathy?
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Brain; Carbazoles; Carvedilol; Computed Tom | 2016 |
Severe circadian hypertension in a young man.
Topics: Amlodipine; Angioplasty, Balloon; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Ci | 2011 |